$AMBS Taken together, these three subsidiaries of AMBS are developing orphan therapeutic assets that are in areas of neurology, regenerative medicine and ophthalmology where competition is limited, and where each program has the potential to become ‘standard of care’ for multiple indications.”

https://financialstrend.com/two-themes-could-...46629.html